References: 51-103: Understanding Neuropathic Pain

51. Bartusch, SL, et al, Clonazepam for the Treatment of Lancinating Phantom Limb Pain. 12:59-62, 1996.

52. Rosner H, et al, Gabapentin Adjunct Therapy in Neuropathic Pain States. 12:56-58, 1996.

53. Xiao W-H, Bennett GJ. Gabapentin has an anti-nociceptive effect mediated via a spinal site of action in a rat model of painful peripheral neuropathy. Analgesia 1997; 2:267-273.

54. Hunter JC, Goas KR, Hedley LR, et al. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmaco 1997; 324:153-160.

55. Singh L, Field MJ, Ferris P, et al. The anti-epileptic agent gabapentin possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology 1996; 127:1-9.

56. Stanfa LC, Singh L, Williams RG, Dickerson AH. Gabapentin, ineffective in normal rats, markedly reduces C-fiber evoked responses after inflammation. Neuroreport 1997; 8:587-590.

57. Hwang JH, Yaksh TL. The effect of intrathecal gabapentin on tactile-evoked allodynia in a surgically-induced neuropathic pain model in the rat. Reg Anesth 1997; 22:249-256.

58. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of post herpetic neuralgia. Neurology 1991;41:1024-1028.

59. Bruera E, Ripamonti C, Brennis C, Macmillan K, Hanson J. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic pain. J Pain Symptom Manage 1992; 7(3):138-140.

60. Elliott JR. Slow Na+ channel inactivation and bursting discharge in a simple model axon: implications for neuropathic pain. Brain Research 754 (1997) 221-226.

61. Omana-Zapata I, Khabbaz MA, Hunter JC, Bley KR. QX-314 inhibits ectopic nerve activity associated with neuropathic pain. Brain Research 771 (1997) 228-237.

62. Glazer S, Portenoy RK, Systemic local anesthetics in pain control, J. Pain Sympt Mgmt 6:30-39, 1991.

63. Kontinen VK, Paananen S, Kalso E. The effects of the - 2 -adrenergic agonist, Dexmedetomidine, in the Spinal Nerve Ligation Model of Neuropathic Pain. Anesth Analg 1998;86:355-360.

64. Eisenach JC, Hood DD, Curry R. Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers. Anesth Analg 1998; 87:591-596.

65. Spaulding TC, Venafro JJ, MaMG, Fielding, S. The dissociation of the antinociceptive effect of clonidine from supraspinal structures. Neuro pharamacol 1979; 18:103-105.

66. De Kock M, Eisenach J, Tong C, et al. Analgesic doses of intrathecal but not intravenous clonidine increase acetylcholine in cerebrospinal fluid in humans. Anesth Analg 1997; 84:800-803.

67. Porchet HC, Piletta P, Dayer P. Pharmacokinetics pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. Eur J Clin Pharmac 1992; 42:655-661.

68. Eisenach J, Detweiler D, Hood D. Hemodynamic and analgesic actions of epidurally administered clonidine. Anesthesiology 1993; 78:277-287.

69. Jevtovic-Todorovic V, Wozniak DF, Powell S, Nardi A, Olney JW. Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects. Brain Research 781 (1998) 202-211.

70. Ziegler D, Lynch SA, Muir J, et al, Transdermal clonidine vs placebo in painful diabetic neuropathy. Pain 48:403-408, 1992.

71. Mac Donald E, Scheinin M. Distribution and pharmacology of alpha 2-adrenoreceptors in the central nervous system. J Physiol pharmacol 1995; 46:241-258.

72. Robbins WR, Staats PS, Levine J, et al. Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth Analg 1998;86:579-583.

73. Dray A. Mechanism of action of capsaicin - like molecules on sensory neurons. Life Sci 1992; 51:1759-1765.

74. Chung JM, Paik KS, Kim JS, et al. Chronic effects of topical application of capsaicin to the sciatic nerve on responses of primate spinothalamic neurons. Pain 1993; 53:311-321.

75. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Review, 43 (1991) 143-201.

76. Cotton P. Compliance problems, placebo effect cloud trials of topical analg. JAMA 1990;264:13-14.

77. Tyring S, Barbarsh RA, et al, Famciclovir for the treatment of acute herpes zoster: effects on acute disease and post-herpetic neuralgia. Arch. Inern. Med. 123:89-96, 1995.

78. Mao J, Price DD, Hayes RL, et al, Intrathecal treatment with dextrorphan or ketamine potently reduces pain related behaviors in a rat model of mononeuropathy. Brain 5:164-168, 1993.

79. Dickenson AH, NMDA receptor antagonists as analgesics. In Progress in Pain Research and Management, vol. 1, Fields, HL, Liebeskind, JC (ed.), IASP Press, Seattle, 1994.

80. Takahashi H, Miyazaki M, Nanbu T, et al. The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case. Pain 75 (1998) 391-394.

81. Malcangio M, Tomlinson DR. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 76 (1998) 151-157.

82. Wegert S, Ossipov MH, Nichols ML, et al. Differential activities of intrathecal MK-801 or morphine to alter responses to thermal and mechanical stimuli in normal or nerve-injured rats. Pain 71 (1997) 56-64.

83. Kohrenhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W and Riederer P. Therapeutic brain concentration of the NMDA antagonist Amantadine, Neuropharmacology, 34 (1995) 713-721.

84. Eisenberg E, Pud D. Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine? Pain 74 (1998) 337-339.

85. Pud D, Eisenberg E, Spitzer A, et al. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain 75 (1998) 349-354.

86. Choe H, Kim JS, Ko SH, Kim DC, Han YJ, Song HS. Epidural verapamil reduces analgesic consumption after lower abdominal surgery. Anesth Analg 1998;86:786-90.

87. Stein C. Opioid treatment of Chronic Non-malignant Pain. Anesth. Analg. 84:912-914, 1997.

88. Benedetti F, Vighetti S, Amanzio M, et al. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 74 (1998) 205-211.

89. Jadad AR, Carroll D, Glynn CJ, Moore RA and McQuay, HJ. Morphine responsiveness of chronic pain: double blind randomised crossover study with patient-controlled analgesia. Lancet, 339 (1992) 1367-1371.

90. Portenoy RK and Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 25 (1986) 171-186.

91. Portenoy RK, Foley KM and Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 43 (1990) 273-286.

92. Dellemijn P, Vanneste J. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997; 349: 753-758.

93. Shibata M, Wakisaka S, Inoue T, et al. The effect of electroconvulsive treatment on thermal hyperalgesia and mechanical allodynia in a rat model of peripheral neuropathy. Anesth Analg 1998;86:584-587.

94. Brewer K, Yezierski RP. Effects of adrenal medullary transplants on pain-related behaviors following excitotoxic spinal cord injury. Brain Research 798, 1998, pp 83-92.

95. Decosterd I, Buchser E, Gilliard N, Saydoff J, Zurn AD, Aebischer P. Intrathecal implants of bovine chromaffin cells alleviate mechanical allodynia in a rat model of neuropathic pain. Pain 76 (1998) 159-166.

96. Yu W, Hao JX, Saydoff J, Haegeeerstrand A. Long term alleviation of allodynia-like behaviors by intrathecal implantation of bovine chromaffin cells in rats with spinal cord injury. Pain 74 (1998) 115-122.

97. Wong CS, Cherng CH, Tung CS. Intrathecal administration of excitatory amino acid receptor antagonists or nitric oxide synthase inhibitor reduced autotomy behavior in rats. Anesth Analg 1998;87:605-608.

98. Lavand'homme P, Pan HL, Eisenach JC. Intrathecal neostigmine, but not sympathectomy, relieves mechanical allodynia in a rat model of neuropathic pain. Anesthesiology, Vol 89, No 2, Aug 1998.

99. Ertas M, Sagduyu A, Arac N, Uludag B, Ertekin C. Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain 75 (1998) 257-259.

100. Cui JG, O'Connor WT, Ungerstedt U, Linderoth B, Meyerson BA. Spinal cord stimulation attenuates augmented dorsal horn release of excitatory amino acids in mononeuropathy via a GABAergic mechanism. Pain 73 (1997) 87-95.

101. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42 (1990) 135 - 144.

102. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the Treatment of Postherpetic Neuralgia. JAMA 280 (1998) 1837 - 1842.

103. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients with Diabetes Mellitus. JAMA 280 (1998) 1831 - 1836.

Updated on: 01/28/13